{
    "xml": "<topic id=\"PHP3063\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/apomorphine-hydrochloride\" basename=\"apomorphine-hydrochloride\" title=\"APOMORPHINE HYDROCHLORIDE\">\n<title>APOMORPHINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_430\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/apomorphine\">Apomorphine</xref>\n</p>\n<data name=\"vtmid\">67939000</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_157437168\" title=\"Dopamine receptor agonists\">Dopamine receptor agonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP45227\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Refractory motor fluctuations in Parkinson's disease ('off' episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (for capable and motivated patients) (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1&#8239;mg, dose to be administered at the first sign of 'off' episode, then 2&#8239;mg after 30&#8239;minutes, dose to be given if inadequate or no response following initial dose, thereafter increase dose at minimum 40-minute intervals until satisfactory response obtained, this determines threshold dose; usual dose 3&#8211;30&#8239;mg daily in divided doses (max. per dose 10&#8239;mg), subcutaneous infusion may be preferable in those requiring division of injections into more than 10 doses; maximum 100&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Refractory motor fluctuations in Parkinson's disease (&#8216;off&#8217; episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (in patients requiring division into more than 10 injections daily) (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1&#8239;mg/hour, adjusted according to response, then increased in steps of up to 500&#8239;micrograms/hour, dose to be increased at intervals not more often than every 4 hours; usual dose 1&#8211;4&#8239;mg/hour, alternatively usual dose 15&#8211;60&#8239;micrograms/kg/hour, change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is a 4-hour treatment-free period at night&#8212;24-hour infusions not recommended unless severe night time symptoms); intermittent bolus doses may be needed; maximum 100&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45480\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Impulse control disorders</p>\n<p>Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45534\" outputclass=\"contraindications\" rev=\"1.11\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Avoid if &#8216;on&#8217; response to levodopa marred by severe dyskinesia or dystonia</ph>; <ph outputclass=\"contraindication\">dementia</ph>; <ph outputclass=\"contraindication\">psychosis</ph>; <ph outputclass=\"contraindication\">respiratory depression</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45619\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Cardiovascular disease</ph>; <ph outputclass=\"caution\">history of postural hypotension (special care on initiation)</ph>; <ph outputclass=\"caution\">neuropsychiatric conditions</ph>; <ph outputclass=\"caution\">pulmonary disease</ph>; <ph outputclass=\"caution\">susceptibility to QT-interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45178\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (apomorphine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35765\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Confusion</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">sudden onset of sleep</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">yawning</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dyskinesia during &#8216;on&#8217; periods (may require discontinuation)</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">haemolytic anaemia (with levodopa)</ph>; <ph outputclass=\"sideEffect\">postural hypotension</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia (with levodopa)</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Eosinophilia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Compulsive behaviour</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45769\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.25\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityContraindications\">\n<sectiondiv>\n<p>Contraindicated if history of hypersensitivity to opioids.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45101\" outputclass=\"pregnancy\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless clearly necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45721\" outputclass=\"breastFeeding\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available; may suppress lactation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45298\" outputclass=\"hepaticImpairment\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35809\" outputclass=\"renalImpairment\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35676\" outputclass=\"monitoringRequirements\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor hepatic, haemopoietic, renal, and cardiovascular function.</p>\n<p>\n<i>With concomitant levodopa</i> test initially and every 6 months for haemolytic anaemia and thrombocytopenia (development calls for specialist haematological care with dose reduction and possible discontinuation).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35721\" outputclass=\"treatmentCessation\" rev=\"1.7\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35854\" outputclass=\"patientAndCarerAdvice\" rev=\"1.25\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\r\n<title>Driving and skilled tasks</title>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Sudden onset of sleep</p>\r\n<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p>\r\n<p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p>\r\n<p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Hypotensive reactions</p>\r\n<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Drugs and Driving</p>\r\n<p>Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient's fitness to drive is available from the Driver and Vehicle Licensing Agency at<xref format=\"html\" href=\"http://www.dvla.gov.uk\">www.dvla.gov.uk</xref>.</p>\r\n<p>2015 legislation regarding driving whilst taking certain drugs, may also apply to apomorphine, see <i>Drugs and driving</i> under <xref format=\"dita\" href=\"#PHP97234\" type=\"bookmark\" namespace=\"/guidance/guidance-on-prescribing\">Guidance on prescribing</xref>.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3063-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/apomorphine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for injection, solution for infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77205\" title=\"Solution for injection\" namespace=\"/drugs/apomorphine-hydrochloride/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77212\" title=\"Solution for infusion\" namespace=\"/drugs/apomorphine-hydrochloride/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"4\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_430\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/apomorphine\" title=\"Apomorphine\" count=\"1\" rel=\"link\">Apomorphine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97234\" namespace=\"/guidance/guidance-on-prescribing\" title=\"Guidance on prescribing\" count=\"1\" rel=\"link\">Guidance on prescribing</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77205\" namespace=\"/drugs/apomorphine-hydrochloride/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77212\" namespace=\"/drugs/apomorphine-hydrochloride/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP3063",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/apomorphine-hydrochloride",
    "basename": "apomorphine-hydrochloride",
    "title": "APOMORPHINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_430",
            "label": "Apomorphine"
        }
    ],
    "vtmid": "67939000",
    "drugClassification": [
        "Dopamine receptor agonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Refractory motor fluctuations in Parkinson's disease ('off' episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (for capable and motivated patients) (under expert supervision)",
                        "html": "Refractory motor fluctuations in Parkinson's disease ('off' episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (for capable and motivated patients) (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 1 mg, dose to be administered at the first sign of 'off' episode, then 2 mg after 30 minutes, dose to be given if inadequate or no response following initial dose, thereafter increase dose at minimum 40-minute intervals until satisfactory response obtained, this determines threshold dose; usual dose 3&#8211;30 mg daily in divided doses (max. per dose 10 mg), subcutaneous infusion may be preferable in those requiring division of injections into more than 10 doses; maximum 100 mg per day.",
                        "html": "<p>Initially 1&#8239;mg, dose to be administered at the first sign of 'off' episode, then 2&#8239;mg after 30&#8239;minutes, dose to be given if inadequate or no response following initial dose, thereafter increase dose at minimum 40-minute intervals until satisfactory response obtained, this determines threshold dose; usual dose 3&#8211;30&#8239;mg daily in divided doses (max. per dose 10&#8239;mg), subcutaneous infusion may be preferable in those requiring division of injections into more than 10 doses; maximum 100&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Refractory motor fluctuations in Parkinson's disease (&#8216;off&#8217; episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (in patients requiring division into more than 10 injections daily) (under expert supervision)",
                        "html": "Refractory motor fluctuations in Parkinson's disease (&#8216;off&#8217; episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (in patients requiring division into more than 10 injections daily) (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "continuous subcutaneous infusion"
                    ],
                    "textContent": "By continuous subcutaneous infusion",
                    "html": "By continuous subcutaneous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 1 mg/hour, adjusted according to response, then increased in steps of up to 500 micrograms/hour, dose to be increased at intervals not more often than every 4 hours; usual dose 1&#8211;4 mg/hour, alternatively usual dose 15&#8211;60 micrograms/kg/hour, change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is a 4-hour treatment-free period at night&#8212;24-hour infusions not recommended unless severe night time symptoms); intermittent bolus doses may be needed; maximum 100 mg per day.",
                        "html": "<p>Initially 1&#8239;mg/hour, adjusted according to response, then increased in steps of up to 500&#8239;micrograms/hour, dose to be increased at intervals not more often than every 4 hours; usual dose 1&#8211;4&#8239;mg/hour, alternatively usual dose 15&#8211;60&#8239;micrograms/kg/hour, change infusion site every 12 hours and give during waking hours only (tolerance may occur unless there is a 4-hour treatment-free period at night&#8212;24-hour infusions not recommended unless severe night time symptoms); intermittent bolus doses may be needed; maximum 100&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Impulse control disorders",
                "textContent": "Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.",
                "html": "<p>Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Avoid if &#8216;on&#8217; response to levodopa marred by severe dyskinesia or dystonia",
                "html": "Avoid if &#8216;on&#8217; response to levodopa marred by severe dyskinesia or dystonia"
            },
            {
                "type": "contraindications",
                "textContent": "dementia",
                "html": "dementia"
            },
            {
                "type": "contraindications",
                "textContent": "psychosis",
                "html": "psychosis"
            },
            {
                "type": "contraindications",
                "textContent": "respiratory depression",
                "html": "respiratory depression"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Cardiovascular disease",
                "html": "Cardiovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "history of postural hypotension (special care on initiation)",
                "html": "history of postural hypotension (special care on initiation)"
            },
            {
                "type": "cautions",
                "textContent": "neuropsychiatric conditions",
                "html": "neuropsychiatric conditions"
            },
            {
                "type": "cautions",
                "textContent": "pulmonary disease",
                "html": "pulmonary disease"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT-interval prolongation",
                "html": "susceptibility to QT-interval prolongation"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (apomorphine).",
                "html": "<p>Appendix 1 (apomorphine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Confusion",
                        "html": "Confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sudden onset of sleep",
                        "html": "sudden onset of sleep",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "yawning",
                        "html": "yawning",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dyskinesia during &#8216;on&#8217; periods (may require discontinuation)",
                        "html": "Dyskinesia during &#8216;on&#8217; periods (may require discontinuation)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "haemolytic anaemia (with levodopa)",
                        "html": "haemolytic anaemia (with levodopa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "postural hypotension",
                        "html": "postural hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia (with levodopa)",
                        "html": "thrombocytopenia (with levodopa)",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Eosinophilia",
                        "html": "Eosinophilia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Compulsive behaviour",
                        "html": "Compulsive behaviour",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "allergyAndCrossSensitivity": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Contraindicated if history of hypersensitivity to opioids.",
                "html": "<p>Contraindicated if history of hypersensitivity to opioids.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless clearly necessary.",
                "html": "<p>Avoid unless clearly necessary.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available; may suppress lactation.",
                "html": "<p>No information available; may suppress lactation.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution.",
                "html": "<p>Use with caution.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor hepatic, haemopoietic, renal, and cardiovascular function.\n\nWith concomitant levodopa test initially and every 6 months for haemolytic anaemia and thrombocytopenia (development calls for specialist haematological care with dose reduction and possible discontinuation).",
                "html": "<p>Monitor hepatic, haemopoietic, renal, and cardiovascular function.</p><p>\n<i>With concomitant levodopa</i> test initially and every 6 months for haemolytic anaemia and thrombocytopenia (development calls for specialist haematological care with dose reduction and possible discontinuation).</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.",
                "html": "<p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Sudden onset of sleep",
                "textContent": "Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.\n\nPatients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.\n\nManagement of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.",
                "html": "<p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>"
            },
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "title": "Hypotensive reactions",
                "textContent": "Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.",
                "html": "<p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>"
            },
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "references": [
                    {
                        "id": "http://www.dvla.gov.uk",
                        "label": "www.dvla.gov.uk"
                    },
                    {
                        "id": "PHP97234",
                        "label": "Guidance on prescribing"
                    }
                ],
                "title": "Drugs and Driving",
                "textContent": "Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient's fitness to drive is available from the Driver and Vehicle Licensing Agency atwww.dvla.gov.uk.\n\n2015 legislation regarding driving whilst taking certain drugs, may also apply to apomorphine, see Drugs and driving under Guidance on prescribing.",
                "html": "<p>Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient's fitness to drive is available from the Driver and Vehicle Licensing Agency at<xref format=\"html\" href=\"http://www.dvla.gov.uk\">www.dvla.gov.uk</xref>.</p><p>2015 legislation regarding driving whilst taking certain drugs, may also apply to apomorphine, see <i>Drugs and driving</i> under <xref format=\"dita\" href=\"#PHP97234\" type=\"bookmark\" namespace=\"/guidance/guidance-on-prescribing\">Guidance on prescribing</xref>.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for injection",
                "solution for infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77205",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77212",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_430",
                "label": "Apomorphine",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97234",
                "label": "Guidance on prescribing",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77205",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77212",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}